RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

RemeGen Co., Ltd., a fully-integrated commercial-stage biotechnology company, announced a clinical research and supply agreement with Innovent Biologics .